Abstract
We have used recent structural advances in our understanding of the N-methyl-d-aspartate (NMDA) receptor amino terminal domain to explore the binding mode of multiple diaryl GluN2B-selective negative allosteric modulators at the interface between the GluN1 and GluN2B amino-terminal domains. We found that interaction of the A ring within the binding pocket seems largely invariant for a variety of structurally distinct ligands. In addition, a range of structurally diverse linkers between the two aryl rings can be accommodated by the binding site, providing a potential opportunity to tune interactions with the ligand binding pocket via changes in hydrogen bond donors, acceptors, as well as stereochemistry. The most diversity in atomic interactions between protein and ligand occur in the B ring, with functional groups that contain electron donors and acceptors providing additional atomic contacts within the pocket. A cluster of residues distant to the binding site also control ligand potency, the degree of inhibition, and show ligand-induced increases in motion during molecular dynamics simulations. Mutations at some of these residues seem to distinguish between structurally distinct ligands and raise the possibility that GluN2B-selective ligands can be divided into multiple classes. These results should help facilitate the development of well tolerated GluN2B subunit-selective antagonists.
Footnotes
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke [Grant NS36654]. D.C.L., J.P.S., and S.F.T. are coinventors on Emory-owned intellectual property, and hold an equity position in NeurOp Inc., which has licensed this intellectual property. J.P.S. and S.F.T. serve as consultants to NeurOp Inc., and D.C.L. serves on the Board of Directors for NeurOp Inc.
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
ABBREVIATIONS:
- NMDA
- N-methyl-d-aspartate
- ATD
- amino-terminal domain
- LBD
- ligand-binding domain
- AMPA
- α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- MD
- molecular dynamics
- RMSF
- root-mean-square fluctuation
- Ro-25-6981
- α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidine propanol
- CP101,606
- traxoprodil
- CP101,581
- 1-[(1R,2R)-1-hydroxy-1-(4-hydroxyphenyl)-2-propanyl]-4-phenyl-4-piperidinol
- Ro 63-1908
- 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol.
- Received March 2, 2012.
- Accepted May 17, 2012.
- Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|